Transfer RNA detection by small RNA deep sequencing and disease association with myelodysplastic syndromes. Guo Y, Bosompem A, Mohan S, Erdogan B, Ye F, Vickers KC, Sheng Q, Zhao S, Li CI, Su PF, Jagasia M, Strickland SA, Griffiths EA, Kim AS. BMC Genomics. 2015 Sep 24;16(1):727.
Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS. Krönke J, Fink EC, Hollenbach PW, MacBeth KJ, Hurst SN, Udeshi ND, Chamberlain PP, Mani DR, Man HW, Gandhi AK, Svinkina T, Schneider RK, McConkey M, Järås M, Griffiths E, Wetzler M, Bullinger L, Cathers BE, Carr SA, Chopra R, Ebert BL. Nature. 2015 Jul 9;523(7559):183-8.
Emadi A, Faramand R, Carter-Cooper B, Tolu S, Ford LA, Lapidus RG, Wetzler M, Wang ES, Etemadi A, Griffiths EA. Presence of isocitrate dehydrogenase (IDH) mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia. Am J Hematology, 2015 May; 90(5):E77-9. Epub 2015 Feb 27.
Pharmacological targeting of β-catenin in normal karyotype acute myeloid leukemia blasts. Griffiths EA, Golding MC, Srivastava P, Povinelli BJ, James SR, Ford LA, Wetzler M, Wang ES, Nemeth MJ. Haematologica. 2015 Feb;100(2):e49-52. Epub 2014 Nov 7.
Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts. Srivastava P, Paluch BE, Matsuzaki J, James SR, Collamat-Lai G, Karbach J, Nemeth MJ, Taverna P, Karpf AR, Griffiths EA. Leuk Res. 2014 Nov;38(11):1332-41.
Low 25(OH) vitamin D3 levels are associated with adverse outcome in newly diagnosed, intensively treated adult acute myeloid leukemia. Lee HJ, Muindi JR, Tan W, Hu Q, Wang D, Liu S, Wilding GE, Ford LA, Sait SN, Block AW, Adjei AA, Barcos M, Griffiths EA, Thompson JE, Wang ES, Johnson CS, Trump DL, Wetzler M. Cancer. 2014 Feb 15;120(4):521-9.
Ho T-C, Jordan CT, LaMere MW, Ashton JM, O'Dwyer, K, Mendler JH, Liesveld JL, Wang ES, Guzman ML, Calvi LM, Becker MW. A Role for IL1RAP in Acute Myelogenous Leukemia Stem Cells Following Treatment and Progression. Poster presentation at the American Society of Hematology annual meeting, Orlando, FL, December 2015.
Griffiths EA, Carter-Cooper B, Ford LA, Lapidus RG, Wetzler M, Wang ES, Etemadi A, Emadi A. Presence of isocitrate dehydrogenase (IDH) mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia (AML). American Society of Hematology annual meeting, San Francisco, CA, poster presentation, December 2014.